The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

NCT02403284 on ClinicalTrials.gov · last registry update 2024-07-22

Finished 28 April 2021, after enrolling 97 people. Primary outcome, as filed: Whole Body Insulin Sensitivity (insulin suppression test). liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Phoenix VA Health Care System
Sponsor type: Fed
Enrollment: 97
Started: 2013-03
Primary completion: 2021-04-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Whole Body Insulin Sensitivity (insulin suppression test)

Conditions studied

Insulin Resistance

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.